Medtronic plc — Form 10-Q Summary
Business context and reporting period
Medtronic is a global medical technology company. This unaudited filing covers the first quarter of fiscal 2020, the three months ended July 26, 2019, compared with the three months ended July 27, 2018. Amounts are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
Financial performance and liquidity
| Metric | Q1 FY2020 | Q1 FY2019 | Change |
|---|---|---|---|
| Net sales | $7,493 | $7,384 | +1% |
| Operating profit | $1,485 | $1,236 | +20% |
| Operating margin | 19.8% | 16.7% | +3.1 percentage points |
| Net income attributable to Medtronic | $864 | $1,075 | -20% |
| Diluted EPS | $0.64 | $0.79 | -19% |
| Operating cash flow | $1,510 | $1,702 | -11% |
| Free cash flow (company-defined, non-GAAP) | $1,209 | $1,411 | -14% |
Gross margin was approximately 68.4%, down from 70.2%, reflecting higher product costs. GAAP net margin attributable to Medtronic was approximately 11.5%, versus 14.6%. Management’s non-GAAP diluted EPS was $1.26 versus $1.17; this measure excludes specified charges and gains and is not directly comparable to GAAP EPS.
Segment sales: Cardiac and Vascular $2,790 (-1%); Minimally Invasive Therapies $2,100 (+2%); Restorative Therapies $2,012 (+3%); Diabetes $592 (+3%). Emerging-market sales grew 8%; non-U.S. developed-market sales declined 1% and U.S. sales rose 1%. Currency reduced sales in non-U.S. markets by $146 million.
Cash and cash equivalents were $5,080 and current investments were $5,603 at July 26, 2019. Current assets were $22,705 against current liabilities of $8,518. Total debt was approximately $26.3 billion ($1.5 billion current and $24.8 billion long-term), up from $25.3 billion at fiscal year-end. Total assets were $91,268 and equity was $50,497.
Material changes versus the prior comparable period
- Revenue rose modestly, while operating profit and operating margin improved. SG&A expense declined to $2,543 from $2,597, and litigation charges fell to $47 from $103.
- Net income and GAAP EPS declined, primarily because interest expense rose to $609 from $242. The current quarter included a $413 million loss on debt extinguishment associated with debt tenders and early redemptions; other operating results were partly offset by favorable currency remeasurement and hedging.
- Operating cash flow and free cash flow declined. Investing cash flow shifted to a $551 million outflow from a $643 million inflow, chiefly reflecting investment purchases and sales. Financing cash use was $274 million, versus $1,573 million, including new debt issuance and repayment of tendered notes.
- In June, the company issued €5.0 billion of Euro-denominated notes, receiving approximately $5.6 billion net, and used the proceeds toward a tender and early redemption of senior notes. The tender covered $4.6 billion of notes for $5.0 billion total consideration.
- The company adopted the lease accounting standard, recording approximately $1.0 billion of right-of-use assets and lease liabilities; management reported no material impact on income or cash flows.
Outlook, commentary, risks and unusual items
- Management emphasized therapy innovation, globalization and value-based healthcare. It cited product adoption and emerging-market growth, while identifying competition, pricing pressure, reimbursement, product approvals, procedural volumes and currency as factors that may affect results. The filing provides no company-wide revenue or EPS guidance.
- The Enterprise Excellence restructuring program is expected to incur $1.6–$1.8 billion of pretax costs, mostly by fiscal 2022, and generate more than $3.0 billion of annual gross savings by the end of fiscal 2022; management expects $500–$700 million of annual gross savings each fiscal year through that period. Cash outlays are expected to be substantially complete by fiscal 2023.
- Management said available cash, current investments and committed credit facilities should meet foreseeable operating needs for at least 12 months. The $3.5 billion revolving credit facility was undrawn; no commercial paper was outstanding. Debt ratings were unchanged at S&P A/A-1 and Moody’s A3/P-2.
- Legal and tax exposures remain important. Accrued litigation was approximately $0.5 billion, but actual outcomes may differ materially. Matters include pelvic mesh claims, a roughly $112 million patent/royalty jury verdict under appeal, environmental remediation, government inquiries, and IRS disputes involving Puerto Rico income allocations. Gross unrecognized tax benefits were $1.9 billion, with $186 million of accrued interest and penalties.
- Other disclosed risks include competitive launches and pricing, foreign-exchange exposure, supply and sterilization capacity, regulatory approvals and product quality, reimbursement changes, cybersecurity, and acquisition integration. The company reported returning to full sterilization capacity in Q1 after diversifying suppliers.
Important facts for investors to verify
- How much of the GAAP earnings decline was driven by the one-time debt extinguishment charge, and how do recurring earnings compare using consistent adjustments?
- Whether the restructuring savings and timing are achieved, and how cumulative restructuring charges and cash outlays track management’s estimates.
- Whether sales growth, particularly in Cardiac Rhythm & Heart Failure, Pain Therapies and U.S. Diabetes, improves amid competitive and replacement-cycle pressures.
- Developments in major litigation, environmental matters and IRS disputes, and any resulting changes to accruals or cash exposure.
- Debt maturity profile, cash and investment availability, and whether liquidity remains adequate after dividends, repurchases and debt service.